X

Drug Profile

CRL 1072

Latest Information Update: 29 Sep 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CytRx Corporation
Developer LadRx Corporation
Class Antibacterials; Antivirals; Surfactants
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Bacterial infections; Hepatitis B; Herpes simplex virus infections

Most Recent Events

23 Sep 2022 CytRx Corporation is now called LadRx Corporation
18 May 2001 An animal study has been added to the Bacterial infections pharmacodynamics section
28 Dec 2000 CRL 1072 is available for licensing (http://www.cytrx.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com